Compare RCI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | GMAB |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | Canada | Denmark |
| Employees | N/A | 2681 |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8B | 20.6B |
| IPO Year | N/A | N/A |
| Metric | RCI | GMAB |
|---|---|---|
| Price | $37.32 | $33.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $34.50 | ★ $40.40 |
| AVG Volume (30 Days) | 954.2K | ★ 1.4M |
| Earning Date | 01-29-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 341.45 | 132.41 |
| EPS | 8.96 | ★ 25.10 |
| Revenue | ★ $15,091,643,989.00 | $3,845,670,022.00 |
| Revenue This Year | $7.48 | $24.85 |
| Revenue Next Year | $5.58 | $16.51 |
| P/E Ratio | ★ $4.14 | $13.02 |
| Revenue Growth | 2.75 | ★ 29.57 |
| 52 Week Low | $23.18 | $17.24 |
| 52 Week High | $40.26 | $33.96 |
| Indicator | RCI | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 63.93 |
| Support Level | $36.38 | $31.37 |
| Resistance Level | $37.46 | $31.91 |
| Average True Range (ATR) | 0.54 | 0.58 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 90.16 | 83.02 |
Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and the Toronto Blue Jays. Rogers' significant exposure to sports also includes ownership stakes in the Maple Leafs, Raptors, Toronto FC, and Argonauts.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.